Information Provided By:
Fly News Breaks for June 25, 2019
Jun 25, 2019 | 06:02 EDT
Stifel analyst Derek Archila initiated Viking Therapeutics with a Buy rating and $14 price target, citing his belief that the IND for VK2809 will be accepted and his view that concerns around the drug's tolerability profile are unwarranted. He is confident that the FDA will allow Viking to initiate a Phase 2b study in biopsy proven non-alcoholic steatohepatitis patients, Archila tells investors.
News For VKTX From the Last 2 Days
There are no results for your query VKTX